Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088114
Status:
COMPLETED
Last Update Posted:
2014-03-06
First Post:
2004-07-20
Brief Title:
STA-4783 and Paclitaxel for Treatment of Solid Tumors
Sponsor:
Synta Pharmaceuticals Corp
Organization:
Synta Pharmaceuticals Corp
Study Overview
Official Title:
A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety toxicity and maximum tolerated dose of single doses of STA-4783paclitaxel in combination when administered intravenously to patients with refractory cancer To determine the pharmacokinetics of STA-4783 and paclitaxel when co-administered
To assess the anti-tumor activity of STA-4783 and paclitaxel when co-administered
To assess the anti-tumor activity of STA-4783 and paclitaxel when co-administered
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None